What side effects do BCMA bispecifics have?

BCMA bispecifics share the CD3-engaging class profile (cytokine release syndrome / CRS, immune effector cell-associated neurotoxicity syndrome / ICANS, cytopenias) plus a BCMA-specific signal that distinguishes them from the GPRC5D bispecifics (talquetamab, etentamig). The defining BCMA signal is severe infection risk driven by profound hypogammaglobulinemia — BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the patient's antibody-producing plasma cells, leading to very low IgG and a sustained risk of opportunistic infection (pneumocystis, CMV reactivation, COVID-19, viral upper respiratory, bacterial pneumonia). Most patients receive prophylactic antimicrobials and IVIG (intravenous immunoglobulin) replacement throughout treatment. CRS is mostly Grade 1–2, concentrated in cycle-1 step-up doses, managed with tocilizumab. ICANS is less common than with BCMA CAR-T and generally reversible. Cytopenias (neutropenia, anemia, thrombocytopenia) are common. By contrast, the GPRC5D bispecific talquetamab has dysgeusia (taste loss), skin, and nail changes as its patient-noticeable signal rather than the BCMA-specific infection burden.

How do I find a BCMA bispecific clinical trial?

Use ClinTrialFinder's AI-powered matching to surface BCMA bispecific trials based on your specific situation — line of therapy, prior anti-CD38 / PI / IMiD exposure, transplant status, BCMA-prior exposure (most teclistamab and elranatamab trials require BCMA-naïve), and disease stage. Start at /drugs/select-cancer?drug=teclistamab to enter the multiple myeloma matching wizard via the most-established BCMA bispecific entry point. The wizard will also surface relevant elranatamab and linvoseltamab trials in the same setting. Patients who have already progressed on a BCMA bispecific or BCMA CAR-T should ask specifically about non-BCMA target classes (GPRC5D via talquetamab / etentamig, FcRH5 via cevostamab) — see the related talquetamab page for those options.

← Mechanism / Class Hubs | Sibling: GPRC5D · PSMA · HER2 ADCs · CLDN18.2 · Bispecific IO · KRAS · TROP2 ADCs · CDK4/6 · PARP →

65 BCMA × CD3 Bispecific Multiple Myeloma Clinical Trials Recruiting Now (July 2026): Teclistamab, Elranatamab, Linvoseltamab + Cevostamab (FcRH5, Related Class)

Last updated: July 1, 2026

📌 Why this page exists: BCMA × CD3 bispecific T-cell engagers are the largest immunotherapy class in multiple myeloma after BCMA CAR-T. Three drugs are FDA-approved (teclistamab / Tecvayli, elranatamab / Elrexfio, linvoseltamab / Lynozyfic). This hub aggregates all 65 recruiting BCMA bispecific trials across the three approved drugs — plus the related FcRH5 × CD3 bispecific cevostamab and the JNJ-79635322 BCMA × GPRC5D dual-bispecific Phase 3 — so patients, hematologists, and researchers can scan the BCMA-bispecific landscape at one URL. Per-drug pages cover each drug in depth: teclistamab, the elranatamab and linvoseltamab pages are planned. For patients whose disease has progressed on BCMA, the non-BCMA sequencing class is GPRC5D — see our talquetamab (Talvey) page.

What Is BCMA × CD3 Bispecific Therapy?

A BCMA × CD3 bispecific is an antibody with two distinct binding arms. One arm binds BCMA (B-cell maturation antigen, also known as TNFRSF17) — a cell-surface receptor highly expressed on plasma-cell-lineage tumor cells in multiple myeloma. The other arm binds CD3 on T cells. By tethering a T cell directly to a BCMA-expressing tumor cell, the bispecific redirects the patient's own immune system to attack the myeloma — an off-the-shelf, ready-now alternative to BCMA CAR-T (which requires leukapheresis and 3–6 weeks of cell manufacturing).

Why BCMA? BCMA is the most-validated plasma-cell-restricted target in MM after CD38. It is expressed on plasma cells (both malignant and normal), which makes it an effective target but also drives the patient-noticeable side-effect signal: depleting BCMA-expressing plasma cells causes profound hypogammaglobulinemia and a sustained risk of severe infection — the signal that distinguishes BCMA bispecifics from the GPRC5D class (talquetamab).

Administration. All three FDA-approved BCMA bispecifics are subcutaneous with cycle-1 step-up dosing (two priming doses several days apart, then the full treatment dose) to mitigate cytokine release syndrome. The FDA labels currently require inpatient hospitalization for the step-up doses; outpatient administration is being tested in multiple trials below.

The Three Approved BCMA × CD3 Bispecifics + Related Class

Drug	Sponsor	Target	FDA Status	Administration
Teclistamab (Tecvayli, JNJ-64007957)	Janssen Biotech / Johnson & Johnson	BCMA × CD3	Accelerated approval October 25, 2022 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD)	Subcutaneous, step-up dosing in cycle 1, inpatient required per label
Elranatamab (Elrexfio, PF-06863135)	Pfizer	BCMA × CD3	Accelerated approval in 2023 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD) — readers should check the current FDA prescribing information for the most up-to-date status	Subcutaneous, step-up dosing in cycle 1, inpatient required per label
Linvoseltamab (Lynozyfic, REGN5458)	Regeneron	BCMA × CD3	Accelerated approval in 2024 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD) — readers should check the current FDA prescribing information for the most up-to-date status	IV infusion (the only BCMA bispecific given IV rather than SubQ), step-up dosing in cycle 1, inpatient required per label
Cevostamab (RG6160) — related class, NOT BCMA	Genentech / Roche	FcRH5 × CD3	Not yet FDA-approved. Phase 3 program in RRMM under way (NCT07555938)	IV infusion, step-up dosing

Cevostamab is included on this page as a related — but distinct — class. Cevostamab targets FcRH5 (Fc receptor-like 5, also called FcRL5), not BCMA. We include it here because (a) it is the other plasma-cell-restricted CD3 bispecific in late-stage MM development, (b) it is one of the leading non-BCMA, non-GPRC5D sequencing options after BCMA failure, and (c) it shares the CD3-engaging class side-effect profile (CRS, ICANS) without the BCMA-specific infection-from-hypogammaglobulinemia burden. The page title makes the BCMA / FcRH5 distinction explicit.

Next-generation: JNJ-79635322 (BCMA × GPRC5D dual-bispecific). Janssen's JNJ-79635322 simultaneously engages both BCMA and GPRC5D on the tumor cell via two tumor-binding arms plus a CD3 arm — a dual-target strategy designed to reduce single-target antigen-escape resistance. The first Phase 3 head-to-head against teclistamab as the active comparator is open (NCT07518186). We include the JNJ-79635322 trial in this hub because it is structured around the BCMA bispecific class as the reference benchmark; talquetamab and etentamig (GPRC5D-only) are covered on the talquetamab page instead.

Drugs at a Glance

Teclistamab (Tecvayli, Janssen) — first-in-class BCMA × CD3 bispecific

The reference benchmark. FDA accelerated approval Oct 25, 2022 on the MajesTEC-1 dataset. Largest Phase 3 program (MajesTEC-4 maintenance, MajesTEC-7 newly diagnosed, the Tal-Tec arm of NCT06208150, and head-to-head vs JNJ-79635322 in NCT07518186). Used as the active comparator in the first MM-bispecific head-to-head Phase 3.

Full teclistamab page → (25 recruiting trials in detail)

Elranatamab (Elrexfio, Pfizer) — second-in-class BCMA × CD3 bispecific

Pfizer's BCMA bispecific. The MagnetisMM program covers late-line single-agent (MagnetisMM-3 / NCT05020236 doublet with daratumumab in the Phase 3 expansion), post anti-CD38 + lenalidomide RRMM (MagnetisMM-32 / NCT06152575), and newly diagnosed transplant-ineligible MM (NCT05623020). MagnetisMM-30 (NCT06215118) combines elranatamab + iberdomide. Multiple maintenance trials (ElMMA NCT06931704 vs daratumumab maintenance; MRD-guided post-transplant NCT06483100; NCT06918002 post-D-VRd) and the ELDORADO Phase 2 (NCT07247097) vs daratumumab + RVd-lite in newly diagnosed transplant-ineligible MM.

25 recruiting trials in the ClinTrialFinder corpus (July 2026).

Linvoseltamab (Lynozyfic, Regeneron) — third-in-class BCMA × CD3 bispecific

Regeneron's BCMA bispecific — the only BCMA bispecific currently given by IV infusion rather than subcutaneously. LINKER-MM-3 (NCT05730036) is the Phase 3 vs elotuzumab + pomalidomide + dexamethasone in RRMM; NCT06932562 is the Phase 3 vs standard of care in transplant-ineligible MM; NCT07393282 randomizes linvoseltamab vs daratumumab in high-risk smoldering MM (the most-watched early-intervention BCMA-bispecific Phase 3); NCT07222761 compares linvoseltamab monotherapy and linvoseltamab + carfilzomib vs standard combinations. Several novel-combination trials with REGN7945 (NCT06669247) and REGN17372 (NCT07455851), and a window-of-opportunity study in NDMM (NCT05828511).

15 recruiting trials in the ClinTrialFinder corpus (July 2026).

Cevostamab (Genentech) — FcRH5 × CD3 (related class, not BCMA)

Genentech's FcRH5 × CD3 bispecific. Not yet FDA-approved. The Phase 3 NCT07555938 (cevostamab + pomalidomide + dexamethasone vs standard of care in previously treated MM) is the registrational trial. NCT05927571 combines cevostamab + elranatamab — the only trial co-administering two CD3 bispecifics with different tumor-binding arms (BCMA + FcRH5). NCT06934044 is the Chinese Phase 1.

3 recruiting MM trials in the ClinTrialFinder corpus (July 2026). Included here as a related-class sequencing option, not as a BCMA bispecific.

Recruiting Trials by Clinical Setting

The 65 recruiting BCMA-bispecific trials below are grouped by the clinical setting most patients and hematologists ask about first — line of therapy + patient context. Each NCT links to ClinicalTrials.gov for current eligibility and study-site details.

Phase 3 in Newly Diagnosed Transplant-Ineligible MM

The largest 2026 trend: moving BCMA bispecifics out of late-line RRMM into front-line transplant-ineligible MM. Four Phase 3 trials are open across the three approved BCMA bispecifics:

NCT05552222 — MajesTEC-7 (Phase 3; Recruiting): Tec-DR (teclistamab + daratumumab + lenalidomide) and Tal-DR (talquetamab + daratumumab + lenalidomide) vs DRd in newly diagnosed transplant-ineligible MM. Includes a BCMA-bispecific induction arm and a GPRC5D-bispecific induction arm in the same trial.
NCT05623020 — MagnetisMM-6 (Phase 3; Recruiting): Elranatamab + daratumumab + lenalidomide vs daratumumab + bortezomib + lenalidomide + dexamethasone (DVRd) in newly diagnosed transplant-ineligible MM. The elranatamab counterpart to MajesTEC-7.
NCT06932562 — Linvoseltamab vs SoC in Transplant-Ineligible MM (Phase 3; Recruiting): Linvoseltamab compared to standard treatment in transplant-ineligible newly diagnosed MM.
NCT07247097 — ELDORADO (Phase 2; Not Yet Recruiting): Elranatamab vs daratumumab in combination with RVd-lite in newly diagnosed transplant-ineligible/deferred MM. Phase 2 but registrationally important.

Phase 3 Post-Transplant Maintenance

NCT05243797 — MajesTEC-4 (Phase 3; Recruiting): Teclistamab + lenalidomide and teclistamab alone vs lenalidomide alone as maintenance after autologous stem cell transplant in NDMM.
NCT06918002 — Elranatamab + Lenalidomide Consolidation/Maintenance vs SoC after D-VRd (Phase 3; Recruiting): Elranatamab consolidation + maintenance vs standard of care after D-VRd induction in transplant-eligible NDMM.
NCT06931704 — ElMMA (Phase 2; Not Yet Recruiting): Elranatamab + lenalidomide vs daratumumab + lenalidomide as post-transplant maintenance in NDMM.
NCT06910124 — Linvoseltamab + Lenalidomide (L2) During NDMM Maintenance (Phase 2; Recruiting): Linvoseltamab added to lenalidomide maintenance to deepen response or redrive MRD negativity after relapse.
NCT06483100 — MRD-Guided Post-Transplant Elranatamab Maintenance (Phase 2; Recruiting).
NCT06207799 — Pre-Transplant Purging + Post-Transplant MRD-Guided Elranatamab Maintenance in High-Risk MM (Phase 2; Recruiting).

Earlier-Line RRMM (Post Anti-CD38 + Lenalidomide; 1–3 Prior Lines)

Phase 3 confirmatory trials that move BCMA bispecifics out of 4+ prior lines into 1–3 prior lines:

NCT06208150 — Tal-Tec / Tal-P Phase 3 (Recruiting): Includes a Tal-Tec (talquetamab + teclistamab) arm in RRMM after anti-CD38 + lenalidomide. The earlier-line read-out for teclistamab in the bispecific-doublet setting.
NCT06152575 — MagnetisMM-32 (Phase 3; Recruiting): Elranatamab vs standard of care in RRMM after prior anti-CD38 antibody and lenalidomide.
NCT05020236 — MagnetisMM-5 (Phase 3; Recruiting): Elranatamab alone and elranatamab + daratumumab in patients with MM who have received other treatments.
NCT05730036 — LINKER-MM-3 (Phase 3; Recruiting): Linvoseltamab vs elotuzumab + pomalidomide + dexamethasone in RRMM.
NCT07222761 — Linvoseltamab Monotherapy or + Carfilzomib vs SoC (Phase 3; Recruiting): Linvoseltamab monotherapy and linvoseltamab + carfilzomib vs standard-of-care combinations in RRMM.
NCT07518186 — JNJ-79635322 vs Teclistamab (Phase 3; Recruiting): First Phase 3 head-to-head in MM bispecifics — the BCMA × GPRC5D dual-bispecific JNJ-79635322 vs teclistamab as the active comparator in 1–3 prior line RRMM.

Late-Line / Triple-Class Refractory RRMM (Currently Approved Setting)

The FDA-approved setting (4+ prior lines, post anti-CD38 + PI + IMiD) and adjacent triple-class refractory combinations:

NCT05932680 — Limited-Duration Teclistamab (Phase 2; Recruiting): Fixed-duration teclistamab in RRMM. Addresses whether stopping treatment after a defined period reduces cumulative infection / hypogammaglobulinemia risk without sacrificing response.
NCT06465316 — Teclistamab + Iberdomide (Phase 1b; Recruiting).
NCT07105059 — Teclistamab + Mezigdomide (Phase 1; Recruiting).
NCT06215118 — MagnetisMM-30 (Phase 1; Recruiting): Elranatamab + iberdomide in RRMM.
NCT06645678 — Mezigdomide + Elranatamab in RRMM (Phase 1/2; Recruiting).
NCT06988488 — Mezigdomide + Elranatamab Dose-Finding (Phase 1/2; Recruiting).
NCT07280013 — Cemsidomide + Elranatamab (Phase 1; Recruiting): Next-generation cereblon modulator with elranatamab.
NCT06711705 — Elranatamab in RRMM (Phase 2; Recruiting).
NCT06138275 — Elranatamab in R/R MM (Phase 2; Recruiting).
NCT06832865 — ELISA in R/R MM (Phase 2; Recruiting): Elranatamab-based combination.
NCT07454382 — Elranatamab + Cyclophosphamide (Phase 2; Recruiting).
NCT07382739 — PRIME-EMD-PMD (Phase 2; Recruiting): Radiotherapy-induced immune priming + elranatamab in RRMM with extramedullary and paramedullary disease.
NCT06799026 — Dendritic Cell / MM Fusion Vaccine + Elranatamab (Phase 1; Recruiting).
NCT06947083 — Elranatamab Post Cilta-Cel in High-Risk Relapsed MM (Phase 2; Recruiting): Tests elranatamab after BCMA CAR-T (cilta-cel) — the post-CAR-T BCMA-rechallenge question.
NCT06997081 — ERd Combination in NDMM (Phase 2; Recruiting): Elranatamab + lenalidomide + dexamethasone in newly diagnosed MM.
NCT06057402 — Elranatamab Post-Trial Access Study (Phase 4; Recruiting): Expanded-access program for MM.
NCT07181941 — Response-Based Linvoseltamab Dose Reduction (Phase 1/2; Recruiting): Tests whether dose can be reduced once response is achieved.
NCT05137054 — Linvoseltamab + Novel Combinations in RRMM (Phase 1; Recruiting).
NCT06669247 — REGN7945 + Linvoseltamab in RRMM (Phase 1/2; Recruiting).
NCT07455851 — REGN17372 + Linvoseltamab in RRMM (Phase 1/2; Recruiting).
NCT03761108 — Linvoseltamab Phase 1/2 in RRMM (Recruiting): Pivotal LINKER-MM-1 / LINKER-MM-2 family study.
NCT05945524 — Single-Cell Immune Analysis of Teclistamab Resistance (Recruiting): Mechanism study.

Newly Diagnosed and Transplant-Eligible MM (Phase 1–2)

NCT05695508 — MajesTEC-5 / GMMG-HD10 / DSMM-XX (Phase 2; Recruiting): Teclistamab-, talquetamab-, and JNJ-79635322-based combinations as induction and maintenance in transplant-eligible NDMM.
NCT05572229 — Teclistamab + Daratumumab or Lenalidomide in Elderly NDMM (Phase 2; Recruiting).
NCT06758375 — Low-Dose Teclistamab Consolidation in NDMM (Phase 2; Recruiting).
NCT07099391 — ALTITUDE (Phase 1/2; Recruiting): Alternating Dara-RVd and Teclistamab-RVd in transplant-eligible standard-risk NDMM.
NCT07107529 — EMN 37 FITFIX FOR FRAIL (Phase 2; Recruiting): Dara + Tec or Dara + Tal fixed-duration in frail NDMM.
NCT05828511 — Linvoseltamab Window-of-Opportunity in NDMM (Phase 1/2; Recruiting).
NCT06376526 — IMMUNOPLANT in NDMM (Phase 2; Recruiting): Linvoseltamab-based regimen.

MRD-Driven Consolidation (Newly Diagnosed)

NCT06505369 — Teclistamab + Talquetamab Sequential Consolidation in TE NDMM (Phase 2; Recruiting).
NCT06993675 — ROTATE (Phase 2; Recruiting): MRD-positive response-adaptive consolidation with teclistamab + talquetamab.

High-Risk Smoldering MM (Early Intervention)

The 2026 frontier: moving BCMA bispecifics in before active MM in patients who would otherwise wait for organ damage:

NCT06100237 — REVIVE (Phase 2; Recruiting): Teclistamab + daratumumab in high-risk smoldering MM.
NCT06183489 — Elranatamab in High-Risk Smoldering MM (Phase 2; Recruiting).
NCT07393282 — Linvoseltamab vs Daratumumab in HR-SMM (Phase 3; Recruiting): First randomized Phase 3 of a BCMA bispecific vs standard daratumumab in high-risk smoldering MM. The most-watched early-intervention BCMA-bispecific trial.
NCT06140524 — Linvoseltamab in High-Risk MGUS / SMM (Phase 2; Recruiting): Proof-of-concept that linvoseltamab can eliminate abnormal plasma cells before MM develops.

Outpatient Administration / Step-Up Optimization

The FDA label currently requires hospitalization for cycle-1 step-up doses — the main operational bottleneck for adoption in community oncology. Multiple BCMA-bispecific trials are working on outpatient administration:

NCT05972135 — Outpatient Teclistamab or Talquetamab (Phase 2; Recruiting).
NCT06251076 — Outpatient Teclistamab Step-Up Plan Development (Phase 4; Recruiting).
NCT06421675 — Outpatient + Intermittent Elranatamab Dosing (Phase 2; Recruiting).
NCT06015542 — Self-Administration of Subcutaneous Elranatamab at Home (Phase 2; Recruiting).
NCT07637578 — Outpatient Elranatamab in RRMM (Phase 2; Not Yet Recruiting).
NCT07609940 — Outpatient Linvoseltamab with Tocilizumab Prophylaxis (Phase 4; Not Yet Recruiting).
NCT06920251 — Letermovir Prophylaxis with Elranatamab (Phase 2; Recruiting): Tests whether antiviral prophylaxis reduces the CMV reactivation signal of BCMA bispecifics.
NCT07030517 — Teclistamab Safety in Indian RRMM Patients (Phase 4; Recruiting): Real-world evidence.

AL (Light-Chain) Amyloidosis

AL amyloidosis is a plasma-cell-driven disease that also expresses BCMA — a major non-MM use case for BCMA bispecifics:

NCT06649695 — Teclistamab in Previously Treated AL Amyloidosis (Phase 2; Recruiting).
NCT06699394 — Prospective Teclistamab in Systemic AL Amyloidosis (Recruiting).
NCT06935162 — Teclistamab in Previously Treated AL Amyloidosis (Phase 2; Recruiting).
NCT07079423 — Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis (Phase 2; Recruiting): Highest-risk AL subgroup.
NCT07110844 — Teclistamab + Daratumumab in AL Amyloidosis (Phase 2; Recruiting).
NCT07638683 — Teclistamab + Daratumumab in NDMM with Concurrent AL (Phase 2; Recruiting).
NCT06569147 — Elranatamab in Relapsed/Refractory AL Amyloidosis (Phase 1/2; Recruiting).
NCT07524634 — Elranatamab Dose-Schedule Study in Newly Diagnosed AL Amyloidosis (Phase 2; Not Yet Recruiting).
NCT06292780 — Linvoseltamab in R/R Systemic AL Amyloidosis (Phase 1/2; Recruiting).

Cevostamab (FcRH5 × CD3, Related Class)

FcRH5 is a separate plasma-cell-restricted target. Cevostamab is not BCMA, but is the leading non-BCMA, non-GPRC5D CD3 bispecific in MM development — a sequencing option for patients whose disease has progressed on BCMA bispecifics:

NCT07555938 — Cevostamab + Pomalidomide + Dexamethasone vs SoC in Previously Treated MM (Phase 3; Recruiting): Registrational Phase 3.
NCT05927571 — Cevostamab + Elranatamab in R/R MM (Phase 1; Recruiting): Co-administration of two CD3 bispecifics with different tumor-binding arms (BCMA + FcRH5).
NCT06934044 — Cevostamab in Chinese R/R MM Patients (Phase 1; Recruiting).

Trials Not Yet Recruiting (Selected)

Pipeline trials that are likely to open during the second half of 2026:

NCT07428369 — Linvo-VR vs DVRd in Transplant-Eligible NDMM (Phase 2/3; Not Yet Recruiting).
NCT07463807 — Teclistamab + Pomalidomide vs KPd Fixed-Duration in Early Relapse (Phase 1/2; Not Yet Recruiting).
NCT06948084 — Dara + Teclistamab vs DPd or DKd in High-Risk MM (Phase 2; Not Yet Recruiting).
NCT06880601 — TALIM (Phase 2; Not Yet Recruiting): Teclistamab + autologous lymphocyte infusion in RRMM.
NCT07605416 — QUANTUM (Phase 2; Not Yet Recruiting): Quadruplet induction + teclistamab consolidation in primary plasma cell leukemia.

Showing 65 recruiting interventional BCMA × CD3 bispecific trials (teclistamab 25 + elranatamab 25 + linvoseltamab 15) and 3 recruiting cevostamab (FcRH5, related class) trials in the ClinTrialFinder corpus as of June 16, 2026. Not-yet-recruiting trials are listed separately. For the latest searches: teclistamab, elranatamab, linvoseltamab, cevostamab.

Comparison vs Alternative MM Bispecific Classes

BCMA × CD3 is the largest CD3-engaging bispecific class in MM, but it is not the only one. When BCMA bispecifics fail or are not appropriate, the practical alternatives are:

GPRC5D × CD3 (talquetamab) — the first non-BCMA target class to reach FDA approval (talquetamab, August 2023). Different target, different side-effect signal (dysgeusia / skin / nail changes instead of BCMA's infection signal). See our GPRC5D × CD3 Bispecifics Hub for the full GPRC5D landscape (25 recruiting trials — talquetamab + JNJ-79635322 dual-bispecific + SIM0500 trispecific + post-BCMA sequencing); the in-depth talquetamab page is at talquetamab (Talvey).
BCMA × GPRC5D dual-bispecific (JNJ-79635322) — simultaneously engages both BCMA and GPRC5D on the tumor cell, designed to reduce single-target antigen-escape resistance. The first Phase 3 (NCT07518186) uses teclistamab as the active comparator.
FcRH5 × CD3 (cevostamab) — a third target class, separate from both BCMA and GPRC5D. Not yet approved, Phase 3 in progress.

Cross-trial efficacy comparisons between the three approved BCMA bispecifics — or between BCMA, GPRC5D, and FcRH5 — have not been validated in head-to-head randomized trials and should not be inferred from response-rate differences across separate single-arm studies. The choice of which bispecific or which target class is right for a specific patient is a discussion with the patient's hematologist.

Side Effects (BCMA-Class Signal)

BCMA bispecifics share the broader CD3-engaging bispecific class profile but carry a BCMA-specific signal that distinguishes them from the GPRC5D class:

Severe infections and hypogammaglobulinemia (BCMA-specific) — the defining BCMA-bispecific signal. BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the patient's antibody-producing plasma cells, leading to profoundly low IgG and a sustained risk of severe opportunistic infections (pneumocystis, CMV reactivation, viral upper respiratory infections, COVID-19, bacterial pneumonia). Prophylactic antimicrobials and IVIG (intravenous immunoglobulin) replacement are typically part of supportive care throughout treatment. This is the patient-noticeable signal that makes BCMA bispecific supportive care different from talquetamab (GPRC5D, dysgeusia / skin / nail).
Cytokine release syndrome (CRS) (class-shared) — mostly Grade 1–2, concentrated in cycle-1 step-up doses, generally manageable with tocilizumab. The inpatient hospitalization requirement for cycle-1 step-up doses is specifically to monitor for CRS.
Immune effector cell-associated neurotoxicity syndrome (ICANS) (class-shared) — less frequent than with BCMA CAR-T, generally reversible. Confusion, headache, motor weakness, rarely seizures.
Cytopenias (class-shared) — neutropenia, anemia, thrombocytopenia. Manageable with supportive care, growth factor support, and dose modification.
Injection site reactions (teclistamab + elranatamab only) — subcutaneous administration carries local redness, swelling, or pain. Generally mild. (Linvoseltamab is IV infusion and instead has infusion-related reactions.)

Recently Activated Phase 3 Trials (Jun 2026)

Phase 3 trials that began recruiting in June 2026:

NCT07391657 — AZD0120 (dual-targeted BCMA × CD19 CAR-T) in R/R multiple myeloma (Phase 3, activated 2026-07-01)
NCT06158841 — Etentamig (ABBV-383, BCMA × CD3 bispecific) IV monotherapy vs standard available therapies in multiple myeloma (Phase 3, activated 2026-07-01)
NCT07258511 — JNJ-79635322 (BCMA × GPRC5D dual bispecific) vs anti-BCMA × CD3 bispecific antibody in multiple myeloma (Phase 3, activated 2026-06-06) — dual-target vs single-target BCMA class comparison

By contrast, the GPRC5D bispecific talquetamab has its own patient-noticeable signal (dysgeusia / taste loss, skin changes, nail changes) reflecting where GPRC5D is normally expressed (keratinized tissues), but generally less severe infection burden than the BCMA class. Cevostamab (FcRH5) shares the CRS / ICANS class signal but does not deplete normal plasma cells as profoundly as BCMA, so the infection burden is typically less prominent (though pivotal datasets are still maturing).

Frequently Asked Questions

What is BCMA × CD3 bispecific therapy?

A BCMA × CD3 bispecific is an antibody with two binding arms. One arm binds BCMA (B-cell maturation antigen) — a target highly expressed on plasma-cell-lineage tumor cells in multiple myeloma — and the other arm binds CD3 on T cells. By tethering a T cell directly to a BCMA-expressing tumor cell, the bispecific redirects the patient's own immune system to attack the myeloma. All three FDA-approved BCMA bispecifics (teclistamab / Tecvayli, elranatamab / Elrexfio, linvoseltamab / Lynozyfic) require cycle-1 step-up dosing to mitigate cytokine release syndrome (CRS); FDA labels currently require inpatient hospitalization for the step-up doses, and outpatient administration is being tested.

Which BCMA bispecific is best for my multiple myeloma?

There is no published randomized head-to-head trial of teclistamab vs elranatamab vs linvoseltamab in late-line RRMM. Cross-trial efficacy ranges look broadly similar, so the choice is best framed as options to discuss with your hematologist: insurance coverage, your transplant center's experience with each drug, dosing-interval preferences, route of administration (teclistamab and elranatamab are SubQ; linvoseltamab is IV), and which trial slots are open near you. The JNJ-79635322 Phase 3 (NCT07518186) is the first randomized head-to-head in MM bispecifics — using teclistamab as the active comparator vs the BCMA × GPRC5D dual-bispecific.

What is BCMA bispecific prep and administration like?

All three FDA-approved BCMA bispecifics use cycle-1 step-up dosing — two priming doses several days apart, then the full treatment dose — to reduce severe CRS risk. FDA labels currently require inpatient hospitalization for the cycle-1 step-up doses. After cycle 1, dosing transitions to weekly or every-other-week schedules depending on the drug. Prep includes premedications (steroids, antipyretics, antihistamines), IV hydration, and an infection-prophylaxis plan (IVIG, anti-PJP and antiviral prophylaxis). Teclistamab and elranatamab are subcutaneous injections; linvoseltamab is given by IV infusion. Self-administration at home and fully outpatient administration are being tested (NCT06015542, NCT06421675, NCT05972135, NCT06251076, NCT07637578, NCT07609940).

What are the main side effects of BCMA bispecifics?

The defining BCMA-bispecific signal is severe infection risk driven by hypogammaglobulinemia — BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the antibody-producing plasma cells, leading to very low IgG and a sustained risk of opportunistic infection. Prophylactic antimicrobials and IVIG replacement are typically part of supportive care. The class-shared CD3-engaging signals are cytokine release syndrome (CRS) (mostly Grade 1–2, cycle-1, managed with tocilizumab), immune effector cell-associated neurotoxicity syndrome (ICANS) (less frequent than with CAR-T, generally reversible), and cytopenias (neutropenia, anemia, thrombocytopenia). By contrast, the GPRC5D class (talquetamab) has dysgeusia / skin / nail changes as its patient-noticeable signal rather than the BCMA infection burden.

How do I access a BCMA bispecific clinical trial?

Use ClinTrialFinder's AI-powered matching to surface BCMA bispecific trials based on your specific situation — line of therapy, prior anti-CD38 / PI / IMiD exposure, transplant status, BCMA-prior exposure (most teclistamab and elranatamab trials require BCMA-naïve), and disease stage. Start from the patient-match button below; the wizard routes through teclistamab as the most-established BCMA bispecific entry point and will surface relevant elranatamab and linvoseltamab trials in the same setting. Patients who have already progressed on a BCMA bispecific or BCMA CAR-T should also see the talquetamab (GPRC5D) page for the non-BCMA sequencing class.

Find Matching BCMA Bispecific Trials

Use ClinTrialFinder's AI-powered matching to find teclistamab, elranatamab, linvoseltamab, and cevostamab trials based on your line of therapy, prior treatments, and disease stage.

Find Matching BCMA Bispecific Trials

This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or hematologist. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here. FDA approval dates and indications are summarized for context only; consult the current FDA prescribing information for each drug for authoritative regulatory status.